The first concrete result was achieved with ladostigil (Figure 1), a dual inhibitor of AChE (reversible) and MAO-B (irreversible), currently in clinical trials (NCT01354691) as an anti-AD drug [17]. Here, MAOB is linked to Alzheimer disease.